Knowledge Hub

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016

Press Release   •   Jan 04, 2017 06:39 EST

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

View Full Report at http://www.marketresearchreports.biz/analysis/901209

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.

- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

- Analysis of partnership and licensing deals based on clinical stage of development of products.

- Summary of the pharmaceutical deals globally in the five quarters.

- Information on the top deals happened in the pharmaceutical industry.

- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Get Sample Copy Of This Report @ http://www.marketresearchreports.biz/sample/sample/901209

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.

- Find out the major deal performing segments for investments in your industry.

- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

- Identify companies that are aggressively looking to raise capital in the market

- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

- Identify growth segments and opportunities in each region within the industry.

- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 11

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2016 15

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2016 15

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2016 17

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2016 18

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2016 19

2.4.1 Teva Pharma Raises USD15 Billion in Public Offering of Notes 19

2.4.2 Pfizer Acquires Medivation in Tender Offer 20

2.4.3 Shire Raises USD12.1 Billion in Public Offering of Notes 21

2.4.4 Gilead Sciences Raises USD5 Billion in Public Offering of Notes 21

2.4.5 Johnson & Johnson to Acquire Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 22

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 23

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2016 23

3.1.1 Top M&A Deals in Q3 2016 24

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2015 - Q3 2016 25

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2016 26

3.2.1 Top Initial Public Offerings in Q3 2016 27

3.2.2 Top Secondary Offerings in Q3 2016 27

3.2.3 Top PIPE Deals in Q3 2016 28

3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2015 - Q3 2016 28

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2016 30

3.3.1 Top Venture Financing Deals in Q3 2016 31

3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32

3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2015 - Q3 2016 33

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2015 - Q3 2016 35

3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2015 - Q3 2016 36

3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2016 37

3.4.1 Top Private Equity Deals in Q3 2016 38

3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2015 - Q3 2016 39

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2015 - Q3 2016 42

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 44

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2016 45

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2016 46

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2016 46

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 47

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2015 - Q3 2016 49

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2015 - Q3 2016 50

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 52

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2016 54

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2016 54

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 56

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2016 57

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2016 58

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2016 58

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2015 - Q3 2016 59

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015 - Q3 2016 61

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 63

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 64

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015 - Q3 2016 66

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.